Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence

References

• Garcia MJA, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global Cancer Facts and Figures 2007. American Cancer Society, GA, USA (2007).
   Google Scholar
• NICE. ERG Report: Erlotinib for the Treatment of Relapsed Non-Small Cell Lung Cancer. The National Institute for Health and Clinical Excellence, Liverpool, UK (2006).
   Google Scholar
• NCCN. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer V.1.2009. National Comprehensive Cancer Network, PA, USA (2009).
   Google Scholar
• Ramsey SD, Howlader N, Etzioni RD, Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results – Medicare. J. Clin. Oncol.22(24), 4971–4978 (2004).
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell Lung Cancer Drugs68(8), 1105–1113 (2008).
   Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol.26(28), 4617–4625 (2008).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol.18(10), 2095–2103 (2000).
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med.353(2), 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM. Second-line and third-line chemotherapy for lung cancer: use and cost. Am. J. Manag. Care14(5), 297–306 (2008).
   PubMed Web of Science ®Google Scholar
• Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol.25(12), 1545–1552 (2007).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol.23(25), 5892–5899 (2005).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist12(7), 840–849 (2007).
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Rossi A et al. Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist14(2), 137–147 (2009).
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L et al. SATURN: a double-blind, randomized, Phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J. Clin. Oncol.27(Suppl.), 15S (2009) (Abstract 8001).
   Web of Science ®Google Scholar
• Miller VA, O’Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, Phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol.27(Suppl.), 18S (2009) (Abstract LBA8002).
   Web of Science ®Google Scholar
• Belani CP, Brodowicz T, Ciuleanu T et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized Phase III study in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.27, CRA8000 (2009).
   Google Scholar
• Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer – molecular and clinical predictors of outcome. N. Engl. J. Med.353(2), 133–144 (2005).
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet372(9652), 1809–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Jones D. Avastin–Tarceva combination fails in lung cancer. Nat. Biotechnol.27(2), 108–109 (2009).
   PubMedGoogle Scholar
• Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ317(7161), 771–775 (1998).
   PubMed Web of Science ®Google Scholar
• Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist13(11), 1201–1204 (2008).
   PubMedGoogle Scholar
• Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin. J. Oncol. Nurs.12(2), 283–290 (2008).
   PubMedGoogle Scholar
• Perez-Soler R, Delord JP, Halpern A et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist10(5), 345–356 (2005).
   PubMed Web of Science ®Google Scholar
• Tsuboi M, Le Chevalier T. Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Med. Oncol.23(2), 161–170 (2006).
   PubMedGoogle Scholar
• Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer51(1), 115–121 (2005).
   Google Scholar
• van Zandwijk N. Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics. Lung Cancer51(1), 137–138 (2006).
   PubMedGoogle Scholar
• Ramsey SD, Clarke L, Kamath TV, Lubeck D. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J. Manag. Care Pharm.12(6), 472–478 (2006).
   PubMed Web of Science ®Google Scholar
• Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health12(1), 20–27 (2008).
   Google Scholar
• Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer61(3), 405–415 (2008).
   PubMed Web of Science ®Google Scholar
• Pompen M, Novak A, Postmus P. Cost-effectiveness analysis of erlotinib in the Netherlands. Value Health9(6), A203 (2006).
   Google Scholar
• Terres R, Sanz A, Gylmark M. Pharmacoeconomic analysis in spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced nonsmall cell lung cancer who have failed previous chemotherapy regimens. Value Health9(6), A283 (2006).
   Google Scholar
• Lewis G, Morlotti L, Creeden J. Cost –effectiveness of erlotinib compared with docetaxel for the treatment of relapsed nonsmall cell lung cancer (NSCLC) in the UK. Value Health9(6), A203 (2006).
   Google Scholar
• Orlewska E, Szczesna A, Gyldmark M. Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer (NSCLC) in poland. Value Health9(6), A280 (2006).
   Google Scholar
• Côté I, Leighl N, Gyldmark M, Maturi B. Pharmacoeconomic analyses of erlotinib compared with best supportive care (BSC) for the treatment of relapsed non-small cell lung cancer (NSCLC) from the canadian public health care perspective. Value Health9(6), A279 (2006).
   Google Scholar